October 9 - 12, 2012
Building 10 & Natcher Conference Center
- General Schedule of Events
- Opening Plenary Session
- Concurrent Symposia Sessions
- Poster Sessions
- National Graduate Student Research Conference
- FARE Award Ceremony
- Special Exhibits on Resources for Intramural Research
- TSA Research Festival Exhibit Show
- Clinical Center Tours
- Research Festival Committees
- Past Research Festivals
Systematic analysis of potential targets for immunotherapy in acute myeloid leukemia
| Wednesday, November 06, 2013 — Poster Session I | |||
|---|---|---|---|
4:00 p.m. – 6:00 p.m. |
FAES Academic Center (Upper-Level Terrace) |
NHLBI |
CANCER-4 |
Authors
- M. Goswami
- M. Bhagwat
- L. Young
- H.M. Sardon
- A.L. Williams
- J.P. McCoy
- S. Ito
- S.A. Strickland
- B.N. Savani
- J.W. Fraser
- H. Sadrzadeh
- A.T. Fathi
- L. Qin
- A. Hess
- B.D. Smith
- J.E. Karp
- A.J. Barrett
- C.S. Hourigan
Abstract
Treatment in the non-transplant setting for adults with acute myeloid leukemia (AML) depends on the ability to target leukemic clones while sparing normal tissues. Many leukemia-associated antigens (LAA) have been identified, but an evidence-based list of targets in AML has not been established. Thus, we profiled the expression of 75 LAAs from 48 de-identified, clinically annotated primary AML patients. Gene expression was assayed using RQ-PCR on custom-designed arrays. 8 blood samples were further characterized by flow sorting into bulk leukemia and enriched stem cell populations. 51 genes were over-expressed by at least 5-fold in at least one patient, and several distinct patterns of over-expression were observed in AML patients compared to healthy donors. The presence of the FLT3-ITD mutation was strongly statistically associated with high WT1 levels, and WT1-negative samples expressed significantly lower levels of ERG, BAALC, and KIT – all factors associated with poor prognosis in AML. The heterogeneity and patterns of over-expression observed suggest that targeting a single antigen is ineffective because of the vast diversity of disease, but based on our data, it may be possible to create a panel of multiple targets with coverage of all AMLs, eliminating the need for costly individualized personalization of therapy.
